<DOC>
	<DOCNO>NCT00781105</DOCNO>
	<brief_summary>The `` Chinese PAC '' study ( CLDT600ACN03 ) evaluate efficacy safety open label telbivudine 2,200 compensate Chronic Hepatitis B ( CHB ) adult . The primary objective study proportion patient achieve undetectable HBV DNA week 52 .</brief_summary>
	<brief_title>Efficacy Safety Telbivudine 600mg Tablets Chinese Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male female 16 65 year age Documented CHB define detectable serum HBsAg serum HBV DNA level Willing able comply study drug regimen Written inform consent assessment Patient history of/or clinical signs/symptoms hepatic decompensation Patient history HCC finding suggestive possible HCC Patient receive treatment nucleoside nucleotide drug whether approve investigational time History hypersensitivity drug ( telbivudine ) drug similar clinical class Patient receive IFN immunomodulatory treatment 12 month screen Previous treatment history NRTIs Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Adult</keyword>
	<keyword>HBV DNA suppression</keyword>
	<keyword>Telbivudine</keyword>
</DOC>